WO2010013141A3 - Substantially pure rosiglitazone hydrogen sulfate - Google Patents

Substantially pure rosiglitazone hydrogen sulfate Download PDF

Info

Publication number
WO2010013141A3
WO2010013141A3 PCT/IB2009/006732 IB2009006732W WO2010013141A3 WO 2010013141 A3 WO2010013141 A3 WO 2010013141A3 IB 2009006732 W IB2009006732 W IB 2009006732W WO 2010013141 A3 WO2010013141 A3 WO 2010013141A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen sulfate
rosiglitazone
oxide
substantially pure
methyl
Prior art date
Application number
PCT/IB2009/006732
Other languages
French (fr)
Other versions
WO2010013141A2 (en
Inventor
Sonny Sebastian
Sasidhar Venkata Balla
Prashant Jagadale
Nitin Sharadchandra Pradhan
Original Assignee
Actavis Group Ptc Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actavis Group Ptc Ehf filed Critical Actavis Group Ptc Ehf
Publication of WO2010013141A2 publication Critical patent/WO2010013141A2/en
Publication of WO2010013141A3 publication Critical patent/WO2010013141A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Provided herein are impurities of rosiglitazone hydrogen sulfate, 4-[2-(N-methyl-2-(N- pyridinyl)amino)ethoxy]bromobenzene (bromo impurity) and 5-[[4-[2-[methyl-(2-pyridinyl- N-oxide)amino]ethoxy]phenyl]methyl]-2,4-thiazolidinedione (N-oxide impurity), and processes for preparing and isolating thereof. Provided further herein is a highly pure rosiglitazone hydrogen sulfate substantially free of bromo and N-oxide impurities, process for the preparation thereof, and pharmaceutical compositions comprising highly pure rosiglitazone hydrogen sulfate substantially free of bromo and N-oxide impurities.
PCT/IB2009/006732 2008-08-01 2009-07-31 Substantially pure rosiglitazone hydrogen sulfate WO2010013141A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1848/CHE/2008 2008-08-01
IN1848CH2008 2008-08-01

Publications (2)

Publication Number Publication Date
WO2010013141A2 WO2010013141A2 (en) 2010-02-04
WO2010013141A3 true WO2010013141A3 (en) 2010-06-17

Family

ID=41479616

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/006732 WO2010013141A2 (en) 2008-08-01 2009-07-31 Substantially pure rosiglitazone hydrogen sulfate

Country Status (1)

Country Link
WO (1) WO2010013141A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
EP1854794A1 (en) * 2006-05-09 2007-11-14 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20070265312A1 (en) * 2006-05-09 2007-11-15 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2007130064A1 (en) * 2006-05-09 2007-11-15 Teva Pharmaceutical Industries, Ltd. 2-n-(5-[[4-(2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20070293546A1 (en) * 2006-06-15 2007-12-20 Srinivasula Reddy Maddula Preparation of rosiglitazone and its salts

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
EP1854794A1 (en) * 2006-05-09 2007-11-14 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20070265312A1 (en) * 2006-05-09 2007-11-15 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2007130064A1 (en) * 2006-05-09 2007-11-15 Teva Pharmaceutical Industries, Ltd. 2-n-(5-[[4-(2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20070293546A1 (en) * 2006-06-15 2007-12-20 Srinivasula Reddy Maddula Preparation of rosiglitazone and its salts

Also Published As

Publication number Publication date
WO2010013141A2 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
WO2011141933A3 (en) Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts
WO2005080358A3 (en) Rosiglitazone phosphate and polymorphic forms
TN2012000557A1 (en) Crystalline form of 4- [5 - [3 -chloro-5 - (trifluoromethyl) phenyl] -4, 5 - dihydro - 5 - (trifluoromethyl) -3 - isoxazolyl] -n- [2-0x0-2- [ ( 2, 2, 2 - trifluoroethyl) amino] ethyl] -1- naphthalenecarboxamide
HK1203959A1 (en) Method for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl -2h-phthalazin-1-one 1-()-4-[5-[(34--4--1-) -2-
CL2008002142A1 (en) Compounds derived from 2-amino-6 - ({[2- (4-chlorophenyl) -1,3-thiazol-4-yl] methyl} thio) -4- [4- (2-hydroxyethoxy) phenyl] pyridin-3 , 5-dicarbonitrile; preparation procedure; Pharmaceutical composition and use in cardiovascular diseases.
WO2008104847A3 (en) Processes for the preparation of pramipexole and salts thereof
PL384446A1 (en) Salt of 5-[[4-[2-(methyl-2-pyridinamino)ethoxy]phenyl]methyl]-2,4-tiazolidynodion with malonic acid and its production method
MX2009009344A (en) Solid forms of a raf kinase inhibitor.
WO2010013141A3 (en) Substantially pure rosiglitazone hydrogen sulfate
WO2009021943A3 (en) Novel preparation process
IL199822A0 (en) Sealed package of pharmaceutical composition comprising 2-n-(5-[[4-(2-methyl-2-pyridinylamino)ethoxy] phenyl] methyl]-2,4-thiazolidinedione)butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
ZA200807190B (en) Process for production of 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-oxo-2-substituted-2,3-dihydro-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate for the process
TW200833323A (en) Prophylactic or therapeutic agent for alopecia
IL219282A0 (en) Process for production of 3 - [5 - [4 - (cyclopentyloxy) - 2 - hydroxybenzoyl] - 2 - [(3 - oxo - 2 - substituted - 2, 3 - dihydro - 1, 2- benzisoxazol - 6 - yl) methoxy]phenyl] propionate ester and intermediate for the process
HU0600347D0 (en) Process for the preparation of {2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one (ziprasidon)
WO2008062244A8 (en) Polymorphs of 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one hydrobromide and processes for preparation thereof
CY2200159T2 (en) 2-N-{5-[[4-[2-METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-2-4-THIAZOLIDINODIONE} BUTANIODIOIC ACID, PREPARATION METHODS AND COMPOSITIONS WITH ROSIGLITAZONE MELEINE
WO2005073227A3 (en) A process for the preparation of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione maleate
WO2008010089A3 (en) Process for preparation of intermediates of rosiglitazone, rosiglitazone and polymorphic forms thereof
DE602005008076D1 (en) PROCESS FOR THE PREPARATION OF ROSIGLITAZONE
HK1057751A1 (en) A thiazolidinedione derivative and its use as antidiabetic
PL385697A1 (en) Salt of 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl] methyl]-2, 4-thiazolidinedione with 1, 5 naphtalene disulfonic acid, and method of its manufacturing
WO2008007390A3 (en) An improved process for purification of zolmitriptan
PL380178A1 (en) Method for the manufacture of 2-[(2, 3, 4-trihydroxiphenyl) methyl) hydrazide D , L-serine hydrochloride
WO2008152653A3 (en) An improved process for the preparation of tamsulosin hydrochloride

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09786209

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 09786209

Country of ref document: EP

Kind code of ref document: A2